Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Butyrate triglyceride, commonly referred to as tributyrin, is a prodrug of butyric acid—a short-chain fatty acid produced by gut microbiota during fiber fermentation. Its relevance to psoriasis arises from butyrate's demonstrated anti-inflammatory and immunomodulatory properties. Preclinical studies, primarily in murine models and cell culture systems, show that butyrate can suppress inflammatory responses by inhibiting histone deacetylases (HDACs), downregulating pro-inflammatory cytokine production (such as TNF-α, IL-6, and IL-17), and promoting regulatory T cell differentiation. These mechanisms are pertinent to psoriasis, a chronic inflammatory disease characterized by dysregulated immune responses and keratinocyte proliferation. However, direct clinical evidence for the use of butyrate triglyceride (tributyrin) in psoriasis patients is currently very limited. Most available data are extrapolated from studies on butyrate's general effects on skin inflammation, gut-skin axis modulation, and systemic immune function. A few small pilot studies and case reports suggest that oral or topical butyrate formulations might improve skin barrier function and reduce psoriatic lesions, but these findings are preliminary and require confirmation in larger, controlled trials. In summary, while there is a plausible scientific rationale and encouraging preclinical data for using butyrate triglyceride in psoriasis, robust clinical evidence is lacking. Thus, the scientific support is modest (rated 2/5), and its use for psoriasis should be considered experimental pending further research.

More about butyrate triglyceride
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by butyrate triglyceride

Products containing butyrate triglyceride